Clinical Trials on Follicular Lymphoma

Total 9651 results

Kami Maddocks
National Cancer Institute (NCI)

Completed

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent... and other conditions

United States
Hoffmann-La Roche

Completed

A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Non-Hodgkin's Lymphoma

United States, Australia, Italy
Hoffmann-La Roche

Terminated

A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

Non-Hodgkin's Lymphoma

United States, Australia, Korea, Republic of, Germany, New Zealand
National Cancer Institute (NCI)

Terminated

506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia | Angioimmunoblastic T-cell Lymphoma and other conditions

United States
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy

Recruiting

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | CD20 Positive | Refractory Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Refractory... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
University of Southampton

Terminated

Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma

Lymphoma

United Kingdom
Associazione Angela Serra per la ricerca sul cancro
Fondazione Italiana Linfomi ONLUS; The International Non-Hodgkin Lymphoma Prognostic...

Completed

Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study)

Lymphoma, Follicular

United States, Spain, Italy, Switzerland, United Kingdom, Argentina, Czechia, France
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma

Lymphoma

United States
MEI Pharma, Inc.
Kyowa Kirin, Inc.

Terminated

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Follicular Lymphoma (FL)

United States, France, Spain, Korea, Republic of, United Kingdom, Belgium, Japan, Taiwan, Australia, Poland, Italy, Canada, Georgia, Greece, Hungary, Netherlands, New Zealand, Serbia, Turkey
Washington University School of Medicine
Genentech, Inc.

Recruiting

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

B Cell Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma | Aggressive Lymphoma | Follicular Lymphoma Grade 3

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Richter Transformation Lymphoma

Poland, United States, Canada, Chile, China, Estonia, Israel, Italy, Korea, Republic of, Spain, Sweden, Turkey, Czechia, Germany, Brazil, Portugal, Ireland, Singapore, United Kingdom, Japan, Peru
Eden BioCell Ltd.
National Taiwan University Hospital

Terminated

RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

Taiwan
BeiGene

Recruiting

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Relapsed Follicular Lymphoma | Refractory Small Lymphocytic Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Diffuse Large B-cell Lymphoma | Transformed Non-Hodgkin Lymphoma | Relapsed... and other conditions

China, Australia
Washington University School of Medicine
Genentech, Inc.

Recruiting

Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed B-Cell Lymphoma | Follicular Lymphoma Grade 3B

United States
New York Medical College
Roswell Park Cancer Institute

Recruiting

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE)

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Non-Hodgkin Lymphoma | Primary Mediastinal B-cell Lymphoma | CD20+ Lymphoblastic Lymphoma | Follicular Lymphoma, Grade III

United States
National Cancer Institute (NCI)

Completed

Study of Lymphoma in Asia

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Leukemia | Hodgkin Lymphoma | Multiple Myleoma | Lympocytic, Follicular

China, Hong Kong, Taiwan
National Cancer Institute (NCI)

Completed

Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Pack Health
Bristol-Myers Squibb; M.D. Anderson Cancer Center

Recruiting

Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy

Lymphoma | Lymphoma, B-Cell | Follicular Lymphoma | Leukemia | Multiple Myeloma | Mantle Cell Lymphoma | Leukemia, Acute Lymphoblastic

United States
Gilead Sciences

Terminated

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Non-FL Indolent Non-Hodgkin's Lymphoma

United States, Canada
BeiGene

Recruiting

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY)

Marginal Zone Lymphoma | Relapsed/Refractory Follicular Lymphoma

United States, Italy, Spain, China, United Kingdom, Australia, Israel, Korea, Republic of, France, Brazil, Ireland, Czechia, Romania, Argentina, Puerto Rico, Austria
Hoffmann-La Roche

Completed

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Lymphoma

United States, France, Germany, Italy, United Kingdom
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

Lymphoma, Non-Hodgkin | Follicular Lymphoma | Diffuse Large B Cell Lymphoma

China
Carevive Systems, Inc.

Completed

Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL

Follicular Lymphoma | Diffuse Large B Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States
University of Arizona

Withdrawn

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (S-BR)

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Mediastinal Large B-cell Lymphoma | Grey Zone Lymphoma | High Grade B Cell Lymphoma

United States
Hoffmann-La Roche

Completed

A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

France
Kite, A Gilead Company

Active, not recruiting

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)

Follicular Lymphoma | Marginal Zone Lymphoma | Indolent Non-Hodgkin Lymphoma

United States, France
iOMEDICO AG
BeiGene Switzerland GmbH

Recruiting

Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma (ARIADNE)

Follicular Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Waldenström's Macroglobulinemia

Germany, Austria
Acepodia Biotech, Inc.

Recruiting

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Marginal Zone Lymphoma | Non Hodgkin Lymphoma | DLBCL | Primary Mediastinal Large B Cell Lymphoma

United States, Taiwan
AIDS Malignancy Consortium
National Cancer Institute (NCI); California Institute for Regenerative Medicine...

Active, not recruiting

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

HIV Infection | Plasmablastic Lymphoma | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult Non-Hodgkin Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Recurrent Burkitt Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Stage III Follicular... and other conditions

United States
Sunesis Pharmaceuticals

Terminated

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Lymphoplasmacytoid Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Grupo Español de Linfomas y Transplante Autólogo...

Completed

Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb

Lymphoma

Spain
Weill Medical College of Cornell University
Epizyme, Inc.; Genentech, Inc.

Recruiting

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin | Follicular Lymphoma | Diffuse Large B Cell Lymphoma

United States
Genmab
AbbVie

Recruiting

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, France, Italy, Spain, United Kingdom, Belgium, Denmark, Netherlands, Finland, Czechia, Sweden, Australia, Norway
Genentech, Inc.

Completed

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (ROMULUS)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, Canada, France, Italy, Germany, Netherlands
Paolo Corradini
Annalisa Chiappella; Cristiana Carniti; Anna Dodero

Recruiting

Italian Observational Study on CAR-T Therapy for Lymphoma (CART-SIE)

Follicular Lymphoma | Mantle Cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Diffuse Low Grade B-Cell Lymphoma

Italy
Mayo Clinic

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Mantle-Cell

United States, Australia, France, Belgium, Turkey, Netherlands, Korea, Republic of
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Double Cord Versus Haploidentical (BMT CTN 1101)

Follicular Lymphoma | Hodgkin Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Burkitt's Lymphoma

United States
oubai, MD/PhD

Recruiting

R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden

Diffuse Large B Cell Lymphoma | Follicular Lymphoma Grade 3B

China
National Cancer Institute (NCI)

Terminated

Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone... and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction

Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse... and other conditions

United States
David Bond, MD

Completed

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

Chronic Lymphocytic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Small Lymphocytic Lymphoma | Richter Syndrome | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Recurrent... and other conditions

United States
Fred Hutchinson Cancer Center
Nektar Therapeutics

Recruiting

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recurrent Grade 3b Follicular Lymphoma | Refractory Grade 3b Follicular... and other conditions

United States
National Cancer Institute (NCI)

Terminated

SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
University of Washington

Recruiting

Tafasitamab, Retifanlimab, and Rituximab in Combination With Chemotherapy (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) for the Treatment of Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 3b Follicular Lymphoma

United States

Clinical Trials on Follicular Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations